|
Cohort1: Poly-ICLC_dose level 1_NY-ESO-1_Montanide
|
| Administration route |
subcutaneous injection |
| Dosage |
0.35 mg |
| Pts |
3 |
| Age |
Adult, Older_Adult |
| Outcome |
Phase I, Number of Participants With SAE and DLT:Serious Adverse Events:0(0.0%); DLT:0(0.0%) |
| Adverse reactions |
No serious clinical adverse events |
|
|
Cohort2: Poly-ICLC_dose level 2_NY-ESO-1_Montanide
|
| Administration route |
subcutaneous injection |
| Dosage |
0.7 mg |
| Pts |
4 |
| Age |
Adult, Older_Adult |
| Outcome |
Phase I, Number of Participants With SAE and DLT:Serious Adverse Events:0(0.0%); DLT:0(0.0%) |
| Adverse reactions |
No serious clinical adverse events |
|
|
Cohort3: Poly-ICLC_dose level 3_NY-ESO-1_Montanide(Dose-escalation component)
|
| Administration route |
subcutaneous injection |
| Dosage |
1.4mg |
| Pts |
3 |
| Age |
Adult, Older_Adult |
| Outcome |
Phase I, Number of Participants With SAE and DLT:Serious Adverse Events:1(33.3%); DLT:0(0.0%) |
| Adverse reactions |
1/3(Cardiac disorders) |
|